Abstract:Background/Aims: Since the first case of novel H7N9 infection was reported, China has experienced five epidemics of H7N9. During the fifth wave, a highly pathogenic H7N9 strain emerged. In order to assess whether the H7N9 vaccine based on A/Zhejiang/DTID-ZJU01/ 2013(H7N9) was effective in protecting against highly pathogenic H7N9, we conducted this study. Methods: Groups of mice were immunized twice by intraperitoneal injection with 500 mu l of either split vaccine alone or MF59- adjuvanted vaccine. Serum was collected 2 weeks after the second vaccine booster. The hemagglutinin inhibition test was conducted on vaccine seed and highly pathogenic H7N9 to evaluate the neutralization of highly pathogenic H7N9. We also immunized mice and challenged them with highly pathogenic H7N9. Mice were observed for illness, weight loss, and death at 1 week and 2 weeks post- infection. Then, the mice were sacrificed and lungs were removed. Antibody responses were assessed and pathological changes in the lung tissue were evaluated. Results: The ability of serum to neutralize highly pathogenic H7N9 was reduced. In mice, highly pathogenic H7N9 was more virulent than A/Zhejiang/DTID- ZJU01/2013(H7N9). After challenge with highly pathogenic H7N9, all mice died while mice challenged with A/Zhejiang/DTID- ZJU01/2013(H7N9) all recovered. The A/ZJU01/PR8/2013 split H7N9 avian influenza vaccine was able to protect against infection with highly pathogenic H7N9 in mice, with or without MF59. Moreover, H7N9 vaccine adjuvanted with MF59 produced high antibody levels, which lead to better protection. Conclusions: The A/ZJU01/PR8/2013 split H7N9 avian influenza vaccine based on A/Zhejiang/DTID- ZJU01/2013( H7N9) is effective in protecting against highly pathogenic H7N9. H7N9 vaccine adjuvanted with MF59 offers better protection against infection with highly pathogenic H7N9. In order to make the H7N9 vaccine applicable to humans, further clinical trials are required to evaluate MF59 adjuvanted vaccine. Meanwhile, the vaccine strain should be updated based on the highly pathogenic H7N9 gene sequence. (C) 2018 The Author(s) Published by S. Karger AG, Basel

Characterization of immune response in mice induced by recombinant vaccinia virus(Tiantan) based multivalent H5N1 avian influenza vaccines

Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection

A Replicating Modified Vaccinia Tiantan Strain Expressing an Avian-Derived Influenza H5N1 Hemagglutinin Induce Broadly Neutralizing Antibodies and Cross-Clade Protective Immunity in Mice.

Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1).

Study on immunogenicity of recombinant lentivirus expressing trimeric HA of swine H1 N1 influenza virus

Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice

The Protective Effects of the A/ZJU01/ PR8/2013 Split H7N9 Avian Influenza Vaccine Against Highly Pathogenic H7N9 in BALB/c Mice.

Immunological Evaluation of Clade 2.2 H5N1 Avian Influenza Inactivated Vaccine Candidate in Mice

RESCUE AND CHARACTERIZATION OF RECOMBINANT AVIAN INFLUENZA VIRUS (H5N2)

A Recombinant Protein Containing Highly Conserved Hemagglutinin Residues 81-122 of Influenza H5N1 Induces Strong Humoral and Mucosal Immune Responses.

Comparative Immunogenicity of Recombinant Adenovirus-Vectored Vaccines Expressing Different Forms of Hemagglutinin (HA) Proteins from the H5 Serotype of Influenza A Viruses in Mice.

Protective Immunity Elicited by a Pseudotyped Baculovirus-Mediated Bivalent H5N1 Influenza Vaccine

A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens

Analysis of Avian Influenza Virus Epitopes and the Design of H5N1 Virus Genetic Engineering Vaccine

A Recombinant Vaccine of H5N1 HA1 Fused with Foldon and Human IgG Fc Induced Complete Cross-Clade Protection Against Divergent H5N1 Viruses.

Evaluation of Oral Immunization with Recombinant Avian Influenza Virus Ha1 Displayed on the Lactococcus Lactis Surface and Combined with the Mucosal Adjuvant Cholera Toxin Subunit B

Characterization of the Immune Responses Elicited by Baculovirus-Based Vector Vaccines Against Influenza Virus Hemagglutinin.

Immunogenicity and Protective Efficacy of a Live Attenuated Vaccine Against the 2009 Pandemic A H1N1 in Mice and Ferrets.

Protection Against Influenza H7n9 Virus Challenge with A Recombinant Np-M1-Hsp60 Protein Vaccine Construct in Balb/C Mice

Preclinical immunogenicity assessment of a cell-based inactivated whole-virion H5N1 influenza vaccine

A replication-deficient H9N2 influenza virus carrying H5 hemagglutinin conferred protection against H9N2 and H5N1 influenza viruses in mice